The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2018 | Therapeutic options for smoldering myeloma
Speaking at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Nicola Giuliani, MD, PhD, from the University of Parma, Parma, Italy, outlines the therapeutic options for patients with smoldering myeloma. While there is no indication to treat monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), smoldering myeloma patients eligible for autologous stem cell transplant can undergo three cycles of induction therapy followed by transplant, a regimen that has proven to improve progression-free and overall survival. For patients that are not eligible for transplant, such as those that are elderly, alternative therapies, including the combination of lenalidomide and dexamethasone have proven to be effective.
